Acumen Pharmaceuticals In... (ABOS)
1.07
-0.00 (-0.47%)
At close: Apr 02, 2025, 3:59 PM
1.08
0.64%
After-hours: Apr 02, 2025, 05:25 PM EDT
-0.47% (1D)
| Bid | 1.04 |
| Market Cap | 64.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.71 |
| PE Ratio (ttm) | -0.63 |
| Forward PE | -1.05 |
| Analyst | Buy |
| Ask | 1.14 |
| Volume | 164,169 |
| Avg. Volume (20D) | 257,910 |
| Open | 1.08 |
| Previous Close | 1.07 |
| Day's Range | 1.05 - 1.08 |
| 52-Week Range | 1.05 - 4.06 |
| Beta | 0.02 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 1, 2021
Employees 61
Stock Exchange NASDAQ
Ticker Symbol ABOS
Website https://acumenpharm.com
Analyst Forecast
According to 3 analyst ratings, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 553.59% from the latest price.
Stock Forecasts7 months ago
-9.03%
Acumen Pharmaceuticals shares are trading lower. T...
Unlock content with
Pro Subscription
